Lone Star Funds Announces Agreement to Acquire Lonza’s Capsules & Health Ingredients Division
Lone Star Funds, a global private equity firm known for investing in companies with strong growth potential, has announced a significant strategic move in the life sciences and healthcare sector. The firm revealed that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (CHI) division from Lonza Group AG. As part of this major transaction, Lonza will retain a 40 percent equity stake in the business, ensuring an ongoing partnership between the two organizations while enabling CHI to operate with greater independence and strategic flexibility.
Overview of the Transaction and Strategic Vision
The agreement marks an important milestone for both Lone Star and Lonza as they seek to unlock the full potential of the CHI division. The transaction reflects Lone Star’s confidence in the growth prospects of CHI and its belief that the business can thrive as a standalone organization focused on innovation, operational excellence and customer-driven solutions.
By maintaining a significant minority stake, Lonza demonstrates its continued commitment to the long-term success of the division while allowing a new ownership structure to guide the next stage of development. The arrangement allows both companies to share in future growth opportunities while leveraging their respective strengths. Lone Star will bring financial resources, operational expertise and a strategic investment approach, while Lonza will remain connected to the business through its equity position and industry knowledge.
Global Presence and Headquarters
The CHI division operates from its global headquarters in Basel, Switzerland, a region recognized as one of the world’s leading hubs for pharmaceutical and life sciences innovation. From this base, the division maintains a significant international footprint, serving customers and partners across the Americas, Europe and the Asia-Pacific region. Its global network of facilities, laboratories and manufacturing sites allows CHI to deliver products and services to a diverse set of pharmaceutical and nutraceutical companies around the world. This geographic reach plays a critical role in supporting the growing demand for advanced capsule technologies, dosage form development and health-focused ingredients.
Structure of the Capsules & Health Ingredients Division
The Capsules & Health Ingredients business is built around three core segments that collectively form a comprehensive platform for customers in the pharmaceutical and nutraceutical industries. These segments include Hard Empty Capsules, Dosage Form Solutions and Health Ingredients. Each segment addresses specific needs within the broader health and wellness ecosystem, enabling CHI to serve clients with integrated solutions that span product formulation, development and manufacturing.
Hard Empty Capsules Segment
The Hard Empty Capsules segment is widely regarded as one of the leading global manufacturers of capsules used in pharmaceutical and nutraceutical products. The division produces both traditional gelatin capsules and innovative plant-based capsule solutions designed to meet evolving consumer and industry demands. With a strong emphasis on quality, safety and performance, the segment offers a broad portfolio of capsule technologies tailored to support drug delivery systems and nutritional supplements.
These capsules play a crucial role in ensuring the stability, effectiveness and user experience of oral medications and dietary products. Through continuous research and development efforts, the segment has introduced numerous innovations that improve dissolution rates, compatibility with active ingredients and sustainability characteristics. Pharmaceutical companies and nutraceutical brands rely on these capsules to package a wide variety of formulations including vitamins, herbal supplements and prescription medicines.
Dosage Form Solutions Platform
Another major component of the CHI division is its Dosage Form Solutions platform, which offers end-to-end development and manufacturing services for customers in both the pharmaceutical and nutraceutical sectors. This segment supports clients throughout the entire product lifecycle, from early-stage formulation development to commercial-scale manufacturing. By combining advanced scientific capabilities with state-of-the-art production facilities, the Dosage Form Solutions business helps companies accelerate the time required to bring new products to market.
The platform provides expertise in formulation design, encapsulation, analytical testing and regulatory compliance, ensuring that products meet stringent quality standards while achieving desired therapeutic or nutritional outcomes. Its integrated approach enables clients to streamline their development processes and focus on innovation while relying on CHI’s technical infrastructure and experience.
Health Ingredients Segment
The Health Ingredients segment focuses on the development and supply of branded, science-backed nutrition ingredients that support a range of health and wellness applications. These ingredients are used by supplement manufacturers and functional food producers to create products that promote joint health, energy levels and active lifestyle benefits. By leveraging extensive scientific research and clinical validation, CHI ensures that its health ingredients deliver measurable benefits and meet regulatory expectations across global markets.
This segment has built a strong reputation among nutraceutical companies for providing reliable ingredients supported by robust scientific data. Its product portfolio addresses some of the most rapidly expanding areas of the global wellness industry, including mobility support, sports nutrition and vitality solutions.
Market Position and Competitive Advantages
Lone Star views CHI as a high-quality and globally recognized platform that possesses several key competitive advantages. These include strong technical capabilities, a broad range of differentiated product offerings and long-standing relationships with customers across the pharmaceutical and nutraceutical industries. The company’s expertise in capsule manufacturing, ingredient development and dosage form technologies positions it as a critical partner for organizations seeking reliable solutions in a highly regulated environment. In addition, CHI’s reputation for product quality and innovation has helped it establish trust with major global brands and emerging health companies alike. This strong market position provides a solid foundation for future growth and expansion under its new ownership structure.
Opportunities for Growth as an Independent Business
With Lone Star’s investment and strategic guidance, CHI is expected to pursue a range of initiatives designed to enhance its operational focus and expand its capabilities. Operating as an independent organization will allow the business to allocate resources more directly toward innovation, research and customer service. Lone Star believes this autonomy will enable the company to respond more quickly to market trends and emerging opportunities within the pharmaceutical and nutraceutical sectors. Potential areas of growth include expanding manufacturing capacity, introducing new capsule technologies, strengthening global supply chains and developing additional science-backed health ingredients that address evolving consumer demands.
Strong Market Demand and Industry Trends
The markets served by CHI are experiencing strong and sustained growth, driven by several long-term trends. Global demand for pharmaceutical products continues to rise as populations age and healthcare systems expand access to treatments. At the same time, consumers are increasingly prioritizing preventive health and wellness, leading to rapid growth in the nutraceutical industry. Dietary supplements, functional foods and health-focused ingredients are becoming integral components of modern lifestyles. These trends create favorable conditions for companies that provide high-quality capsule solutions and scientifically validated nutritional ingredients. CHI is well positioned to benefit from these developments due to its diversified product portfolio and strong presence across multiple geographic regions.
Leadership Perspective from Lone Star
Donald Quintin, Chief Executive Officer of Lone Star Funds, expressed strong confidence in the future prospects of the CHI business following the acquisition agreement. According to Quintin, the division possesses a unique combination of global scale, technical expertise and a long-standing reputation for delivering innovative solutions to customers. He emphasized that Lone Star sees significant opportunity for CHI as a standalone company capable of pursuing strategic initiatives and expanding its leadership within the life sciences sector. Quintin also highlighted the importance of collaboration with the existing CHI management team and Lonza, noting that the partnership will play a key role in driving long-term success and value creation.
Continued Collaboration with Lonza
Even after the transaction is completed, Lonza’s decision to retain a 40 percent equity stake ensures that the company will remain closely connected to the CHI business. This ongoing relationship is expected to foster collaboration in areas such as technology development, operational best practices and market insights. Lonza’s experience and heritage in the life sciences industry provide a valuable foundation that can support CHI’s continued progress under its new ownership structure. By maintaining a shared interest in the company’s performance, both Lone Star and Lonza can work together to guide strategic decisions and support sustainable growth.
The Capsules & Health Ingredients Platform
The acquisition represents an important step in shaping the future of the Capsules & Health Ingredients platform. With strong financial backing, an experienced investment partner and continued collaboration with Lonza, CHI is positioned to strengthen its role as a global leader in capsule manufacturing, dosage form solutions and science-backed nutrition ingredients. The combination of technical expertise, market demand and strategic investment is expected to enable the company to expand its capabilities, deepen customer relationships and develop new innovations that address the evolving needs of healthcare and wellness markets. As the industry continues to evolve, CHI’s ability to deliver high-quality products and integrated solutions will remain central to its long-term growth and success.
Source Link:https://www.businesswire.com/
